We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+69.32%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$408M
AUM Growth
+$136M
Cap. Flow
+$68.1M
Cap. Flow %
16.68%
Top 10 Hldgs %
29.1%
Holding
175
New
29
Increased
78
Reduced
38
Closed
27

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$8.17M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.71M
3
INSM icon
Insmed
INSM
+$4.7M
4
CDTX
Cidara Therapeutics
CDTX
+$4.52M
5
ACLX
Arcellx
ACLX
+$4.35M

Top Sells

Rank Stock Value
1
ANSS
Ansys
ANSS
+$6.01M
2
JNPR
Juniper Networks
JNPR
+$4.58M
3
HES
Hess
HES
+$4M
4
AMED
Amedisys
AMED
+$3.86M
5
WDC icon
Western Digital
WDC
+$2.97M

Sector Composition

Rank Sector Weight
1 Healthcare 59%
2 Technology 12.01%
3 Industrials 6.97%
4 Financials 4.64%
5 Consumer Discretionary 3.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XOMA
26
DELISTED
Xoma
XOMA
$4.07M 1%
105,714
-8,834
-8% -$274K
GH icon
27
Guardant Health
GH
$22.4B
$4.04M 0.99%
64,583
+36,318
+128% +$1.98M
LQDA icon
28
Liquidia Corp
LQDA
$7.98B
$4.01M 0.98%
176,485
+55,844
+46% +$1.21M
RYTM icon
29
Rhythm Pharmaceuticals
RYTM
$7.94B
$3.79M 0.93%
37,482
+9,414
+34% +$874K
SYRE icon
30
Spyre Therapeutics
SYRE
$8.94B
$3.62M 0.89%
215,746
+102,941
+91% +$1.68M
CLDX icon
31
Celldex Therapeutics
CLDX
$3.49B
$3.5M 0.86%
135,258
+28,705
+27% +$665K
GHRS icon
32
GH Research
GHRS
$2.05B
$3.46M 0.85%
241,894
+189,647
+363% +$2.65M
EWTX icon
33
Edgewise Therapeutics
EWTX
$4.89B
$3.38M 0.83%
208,101
+138,378
+198% +$1.96M
AVGO icon
34
Broadcom
AVGO
$1.99T
$3.37M 0.82%
10,200
-2,600
-20% -$798K
META icon
35
Meta Platforms (Facebook)
META
$1.54T
$3.3M 0.81%
4,500
+1,400
+45% +$1.04M
XENE icon
36
Xenon Pharmaceuticals
XENE
$6.19B
$3.3M 0.81%
82,190
+36,570
+80% +$1.29M
APLS
37
DELISTED
Apellis Pharmaceuticals
APLS
$3.3M 0.81%
145,729
+59,066
+68% +$1.38M
PCVX icon
38
Vaxcyte
PCVX
$8.85B
$3.13M 0.77%
86,802
+53,345
+159% +$1.77M
CRM icon
39
Salesforce
CRM
$161B
$3.05M 0.75%
12,885
+1,700
+15% +$429K
ARGX icon
40
argenx
ARGX
$53.8B
$3M 0.74%
4,068
+1,653
+68% +$1.09M
RNAM
41
DELISTED
Avidity Biosciences
RNAM
$2.86M 0.7%
65,580
+24,716
+60% +$999K
AMD icon
42
Advanced Micro Devices
AMD
$762B
$2.78M 0.68%
17,200
+1,800
+12% +$290K
XPO icon
43
XPO
XPO
$23.5B
$2.73M 0.67%
21,080
– –
U icon
44
Unity
U
$19B
$2.69M 0.66%
67,229
+10,129
+18% +$376K
V icon
45
Visa
V
$679B
$2.68M 0.66%
7,861
+1,434
+22% +$496K
VERA icon
46
Vera Therapeutics
VERA
$2.22B
$2.65M 0.65%
91,189
+50,716
+125% +$1.17M
CEG icon
47
Constellation Energy
CEG
$98.5B
$2.5M 0.61%
7,600
-700
-8% -$226K
NVDA icon
48
NVIDIA
NVDA
$5.3T
$2.5M 0.61%
13,400
-2,300
-15% -$401K
HPE icon
49
Hewlett Packard
HPE
$72.3B
$2.42M 0.59%
98,700
+12,500
+15% +$276K
MA icon
50
Mastercard
MA
$495B
$2.39M 0.59%
4,205
+205
+5% +$118K
1
2
3 4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
BCC
Bridge City Capital Lake Oswego, Oregon $361M AUM 38.29% 1-Year Est. Return

HighVista Strategies's Q3 2025 Portfolio in Review

As of Q3 2025, HighVista Strategies held 175 positions worth $408M, up 50% from $272M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

HighVista Strategies deployed $68.1M of net new capital in Q3 2025, opening 29 new positions and adding to 78 existing holdings. Its largest new stake was Cidara Therapeutics: 70,904 shares worth $6.79M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, up from 38% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Western Digital, an estimated $2.97M trimmed.

  • HighVista Strategies's largest Q3 2025 buy was Cidara Therapeutics: 70,904 shares worth $6.79M.
  • HighVista Strategies added most to Abivax in Q3 2025, an estimated $8.17M increase.
  • HighVista Strategies's biggest Q3 2025 reduction was Western Digital, cutting an estimated $2.97M.
  • HighVista Strategies fully exited Ansys in Q3 2025, selling an estimated $6.01M.
  • HighVista Strategies's ten largest holdings make up 29% of its $408M portfolio in Q3 2025.
  • HighVista Strategies opened 29 new positions and closed 27 in Q3 2025.
  • HighVista Strategies's portfolio value rose 50% quarter-over-quarter to $408M.

Based on HighVista Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.